Polypharmacy in Heart Failure with Reduced Ejection Fraction: Progress, Not Problem - 28/08/21
Doi : 10.1016/j.amjmed.2021.03.038
Vishal N. Rao, MD, MPH a, b, Marat Fudim, MD, MHS a, b, Gianluigi Savarese, MD c, Javed Butler, MD, MPH, MBA d, ⁎ 
a Division of Cardiology, Duke University Medical Center, Durham, NC
b Duke Clinical Research Institute, Durham, NC
c Division of Cardiology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden
d Department of Medicine, University of Mississippi Medical Center, Jackson
⁎Requests for reprints should be addressed to Javed Butler, MD, MPH, MBA, Department of Medicine, University of Mississippi Medical Center, 2500 N. State Street, Jackson, MS, 39216.Department of MedicineUniversity of Mississippi Medical Center2500 N. State StreetJacksonMS39216
El texto completo de este artículo está disponible en PDF.
Esquema
| Funding: None. |
|
| Conflicts of Interest: VNR is supported by the National Institutes of Health (NIH) Grant 5T32HL069749-17. MF is supported by a AHA, NHLBI, Mario Family Award, Duke Chair's Award, Bayer, Translating Duke Health Award; he receives consulting fees from AstraZeneca, AxonTherapies, CVRx, Daxor, Edwards LifeSciences, Galvani, NXT Biomedical, Respicardia, and Zoll. GS reports grants and personal fees from Vifor and AstraZeneca, grants and nonfinancial support from Boehringer Ingelheim, personal fees from Società Prodotti Antibiotici, Roche, Servier, GENESIS, Cytokinetics, and Medtronic; grants from Novartis and Boston Scientific. JB serves as a consultant for Abbott, Amgen, Array, AstraZeneca, Bayer, Boehringer Ingelheim, CVRx, Eli Lilly, G3 Pharmaceutical, Impulse Dynamics, Innolife, Janssen, Luitpold, Medtronic, Merck, Novartis, Novo Nordisk, Relypsa, Sequana, StealthPeptide, and Vifor. |
|
| Authorship: All authors have participated in the preparation of the manuscript. |
© 2021
Elsevier Inc. Reservados todos los derechos.
Vol 134 - N° 9
P. 1068-1070 - septembre 2021 Regresar al número
Artículo precedente
- Rediscovering Meaning and Purpose: An Approach to Burnout in the Time of COVID-19 and Beyond
- Steven Southwick, Leonard Wisneski, Patricia Starck
- Polypharmacy in Heart Failure: Progress But Also Problem
- Parag Goyal, Sabrina Mangal, Ashok Krishnaswami, Michael W. Rich
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.
¿Ya suscrito a @@106933@@ revista ?